We found that among the regimens that resulted in LS in NSCLC with PD-L1 ≥50%, PEM+CT ranked first in 1ySR, while CEM monotherapy ranked first in mOS and 2ySR. The gene discussed is CD274; the disease is non-small cell lung carcinoma.